Thursday, April 14, 2011
sanofi-aventis Group has
seized an early stage opportunity that opened up when Biogen Idec Inc. recently
refocused on neurology, by picking up an obesity and type 2 diabetes program
centered on osteocalcin that was
previously held by a Biogen incubator company. sanofi is funding external research
to identify a receptor responsible for the hormone's metabolic effects and is
internally devising strategies to develop osteocalcin or osteocalcin agonists
Escoublac was not idle during its brief life. Karsenty, who
also served as chairman of the company's scientific advisory board, said
substantial progress had been made over the past three years in understanding
how osteocalcin regulates metabolism.
Cain, C. SciBX 4(15); doi:10.1038/scibx.2011.417
Published online April 14, 2011
1. Lee, N.K. et al. Cell 130, 456-469
M. et al. Proc. Natl. Acad. Sci. USA 105, 5266-5270 (2008)
P. BioCentury 15(55), A10; Dec. 24, 2007
S. BioCentury 18(49) A12-A13; Nov. 8, 2010
5. Oury, F. et al. Cell 144, 796-809 (2011)
U. et al. Arterioscler. Thromb. Vasc. Biol. 30, 1474-1478 (2010)
B.B. et al. Eur. J. Endocrinol. 163, 265-272 (2010)
I. et al. Bone 48, 720-725 (2011)
K. et al. Cell 142, 309-319 (2010)
M. et al. Cell 142, 296-308 (2010)
COMPANIES AND INSTITUTIONS MENTIONED
Biogen Idec Inc.
(NASDAQ:BIIB), Weston, Mass.
University, New York, N.Y.
(Euronext:SAN; NYSE:SNY), Paris, France